Loading…

High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)

Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northe...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2016-05, Vol.11 (5), p.e0153744-e0153744
Main Authors: Nguyen Truong, Tam, Laureillard, Didier, Lacombe, Karine, Duong Thi, Huong, Pham Thi Hanh, Phuc, Truong Thi Xuan, Lien, Chu Thi, Nga, Luong Que, Anh, Vu Hai, Vinh, Nagot, Nicolas, Tuaillon, Edouard, Dominguez, Stéphanie, Lemoine, Maud
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223
cites cdi_FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223
container_end_page e0153744
container_issue 5
container_start_page e0153744
container_title PloS one
container_volume 11
creator Nguyen Truong, Tam
Laureillard, Didier
Lacombe, Karine
Duong Thi, Huong
Pham Thi Hanh, Phuc
Truong Thi Xuan, Lien
Chu Thi, Nga
Luong Que, Anh
Vu Hai, Vinh
Nagot, Nicolas
Tuaillon, Edouard
Dominguez, Stéphanie
Lemoine, Maud
description Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northern Vietnam. A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated adults with positive HCV serology completed a standardised epidemiological questionnaire and had a comprehensive liver assessment including hepatic elastography (Fibroscan®, Echosens). From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7-39.6) years, median CD4 count: 504 (361-624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA (median 6.19 (4.95-6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b (69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosis ≥F2 including 24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis, excessive alcohol consumption, estimated time duration from HCV infection, nevirapine and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibrosis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multivariate analysis. Using Fibroscan® as a gold standard, the high thresholds of AST-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs = 0.93, 95%CI: 0.86-0.99 and 0.96 (0.92-0.99), respectively). In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.
doi_str_mv 10.1371/journal.pone.0153744
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1787084579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A453418513</galeid><doaj_id>oai_doaj_org_article_d74130f4e4c440cb8bacb1538a9c2b73</doaj_id><sourcerecordid>A453418513</sourcerecordid><originalsourceid>FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223</originalsourceid><addsrcrecordid>eNqNk99q2zAUxs3YWLtubzA2wWC0sGT6Z0u6GYSwzoHQlrbLrZBlOVZxrFSys-1F9ryTl7Q0pRfFFzbHv-876Ds6SfIewTEiDH29cb1vVTNeu9aMIUoJo_RFcogEwaMMQ_LywfdB8iaEGwhTwrPsdXKAGaJcZPQw-ZvbZQ0uvFs731nXAleBfLYY5dMFmDrbVkZ3pgQXqrOm7QL4ZbsaTMqNanUsz-3GeHBqC--CDeDS3PbW23YJcrOOii7WpuDaG9WtohrYFuTKrmvXLr-As9iwNr4FC2u6Vq3A8eTs8gogjDN88jZ5VakmmHe791Hy8_T79TQfzc9_zKaT-UizVHSjinEBickUVoIpprGAGc6MyginjJVFmpEMCW54pQWENGVUI1GwAhNkRIYxOUo-bn3XjQtyF2mQiHEGeeRFJGZbonTqRq69XSn_Rzpl5f-C80upYnK6MbJkFBFYUUM1pVAXvFC6iIPhSmhcMBK9vu269cXKlDpm4lWzZ7r_p7W1XLqNpDzlGMFocLI1qB_J8slcDjWICGKUZBsU2eNdM-9uexM6ubJBm6ZRrXH9cEZBqYjxsWegnFHGMUkj-ukR-nRoO2qpYi7xFrl4HD2YyglNCUU8RUMc4yeo-JRmZXW81pWN9T3ByZ4gMp353S1VH4KcXV0-nz1f7LOfH7C1UU1XB9f0w0KEfZBuQR0vfPCmuh8CgnLYyrs05LCVcreVUfbh4dzvRXdrSP4B7YkuDw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1787084579</pqid></control><display><type>article</type><title>High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)</title><source>PubMed (Medline)</source><source>Publicly Available Content Database</source><creator>Nguyen Truong, Tam ; Laureillard, Didier ; Lacombe, Karine ; Duong Thi, Huong ; Pham Thi Hanh, Phuc ; Truong Thi Xuan, Lien ; Chu Thi, Nga ; Luong Que, Anh ; Vu Hai, Vinh ; Nagot, Nicolas ; Tuaillon, Edouard ; Dominguez, Stéphanie ; Lemoine, Maud</creator><contributor>Chemin, Isabelle A</contributor><creatorcontrib>Nguyen Truong, Tam ; Laureillard, Didier ; Lacombe, Karine ; Duong Thi, Huong ; Pham Thi Hanh, Phuc ; Truong Thi Xuan, Lien ; Chu Thi, Nga ; Luong Que, Anh ; Vu Hai, Vinh ; Nagot, Nicolas ; Tuaillon, Edouard ; Dominguez, Stéphanie ; Lemoine, Maud ; Chemin, Isabelle A</creatorcontrib><description>Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northern Vietnam. A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated adults with positive HCV serology completed a standardised epidemiological questionnaire and had a comprehensive liver assessment including hepatic elastography (Fibroscan®, Echosens). From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7-39.6) years, median CD4 count: 504 (361-624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA (median 6.19 (4.95-6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b (69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosis ≥F2 including 24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis, excessive alcohol consumption, estimated time duration from HCV infection, nevirapine and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibrosis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multivariate analysis. Using Fibroscan® as a gold standard, the high thresholds of AST-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs = 0.93, 95%CI: 0.86-0.99 and 0.96 (0.92-0.99), respectively). In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0153744</identifier><identifier>PMID: 27148964</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Abuse ; Acquired immune deficiency syndrome ; Adult ; Adults ; AIDS ; Alcohol ; Alcohol abuse ; Alcohol use ; Alcoholic beverages ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral therapy ; Antiviral Agents - therapeutic use ; Biology and life sciences ; Care and treatment ; CD4 antigen ; Cirrhosis ; Coinfection - drug therapy ; Coinfection - epidemiology ; Coinfection - virology ; Complications and side effects ; Cross-Sectional Studies ; Disease control ; Drug abuse ; Drug therapy ; Drugs ; Epidemiology ; Female ; Fibrosis ; Genotypes ; Health aspects ; Health care access ; Health risks ; Hepatitis ; Hepatitis C ; Hepatitis C - complications ; Hepatitis C - drug therapy ; Hepatitis C - epidemiology ; Hepatitis C - virology ; Hepatitis C virus ; Hepatology ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - epidemiology ; HIV Infections - virology ; Hospitals ; Human health and pathology ; Human immunodeficiency virus ; Humans ; Infections ; Infectious diseases ; Life Sciences ; Liver ; Liver cirrhosis ; Liver Cirrhosis - epidemiology ; Liver Cirrhosis - etiology ; Liver Cirrhosis - virology ; Liver diseases ; Liver failure ; Lopinavir ; Male ; Males ; Medicine and health sciences ; Multivariate analysis ; Narcotics ; Nevirapine ; Pathogenesis ; Patients ; People and Places ; Population ; Public health ; Ribonucleic acid ; Risk analysis ; Risk factors ; RNA ; Serology ; Severity of Illness Index ; Substance abuse treatment ; Surveys and Questionnaires ; Tropical diseases ; Vietnam - epidemiology ; Virology</subject><ispartof>PloS one, 2016-05, Vol.11 (5), p.e0153744-e0153744</ispartof><rights>COPYRIGHT 2016 Public Library of Science</rights><rights>2016 Nguyen Truong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2016 Nguyen Truong et al 2016 Nguyen Truong et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223</citedby><cites>FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223</cites><orcidid>0000-0002-0104-9047 ; 0000-0001-8772-9029 ; 0000-0002-3493-2821</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1787084579/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1787084579?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27148964$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.sorbonne-universite.fr/hal-01317436$$DView record in HAL$$Hfree_for_read</backlink></links><search><contributor>Chemin, Isabelle A</contributor><creatorcontrib>Nguyen Truong, Tam</creatorcontrib><creatorcontrib>Laureillard, Didier</creatorcontrib><creatorcontrib>Lacombe, Karine</creatorcontrib><creatorcontrib>Duong Thi, Huong</creatorcontrib><creatorcontrib>Pham Thi Hanh, Phuc</creatorcontrib><creatorcontrib>Truong Thi Xuan, Lien</creatorcontrib><creatorcontrib>Chu Thi, Nga</creatorcontrib><creatorcontrib>Luong Que, Anh</creatorcontrib><creatorcontrib>Vu Hai, Vinh</creatorcontrib><creatorcontrib>Nagot, Nicolas</creatorcontrib><creatorcontrib>Tuaillon, Edouard</creatorcontrib><creatorcontrib>Dominguez, Stéphanie</creatorcontrib><creatorcontrib>Lemoine, Maud</creatorcontrib><title>High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northern Vietnam. A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated adults with positive HCV serology completed a standardised epidemiological questionnaire and had a comprehensive liver assessment including hepatic elastography (Fibroscan®, Echosens). From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7-39.6) years, median CD4 count: 504 (361-624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA (median 6.19 (4.95-6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b (69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosis ≥F2 including 24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis, excessive alcohol consumption, estimated time duration from HCV infection, nevirapine and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibrosis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multivariate analysis. Using Fibroscan® as a gold standard, the high thresholds of AST-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs = 0.93, 95%CI: 0.86-0.99 and 0.96 (0.92-0.99), respectively). In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.</description><subject>Abuse</subject><subject>Acquired immune deficiency syndrome</subject><subject>Adult</subject><subject>Adults</subject><subject>AIDS</subject><subject>Alcohol</subject><subject>Alcohol abuse</subject><subject>Alcohol use</subject><subject>Alcoholic beverages</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral therapy</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biology and life sciences</subject><subject>Care and treatment</subject><subject>CD4 antigen</subject><subject>Cirrhosis</subject><subject>Coinfection - drug therapy</subject><subject>Coinfection - epidemiology</subject><subject>Coinfection - virology</subject><subject>Complications and side effects</subject><subject>Cross-Sectional Studies</subject><subject>Disease control</subject><subject>Drug abuse</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Genotypes</subject><subject>Health aspects</subject><subject>Health care access</subject><subject>Health risks</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - epidemiology</subject><subject>Hepatitis C - virology</subject><subject>Hepatitis C virus</subject><subject>Hepatology</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - virology</subject><subject>Hospitals</subject><subject>Human health and pathology</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - virology</subject><subject>Liver diseases</subject><subject>Liver failure</subject><subject>Lopinavir</subject><subject>Male</subject><subject>Males</subject><subject>Medicine and health sciences</subject><subject>Multivariate analysis</subject><subject>Narcotics</subject><subject>Nevirapine</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>People and Places</subject><subject>Population</subject><subject>Public health</subject><subject>Ribonucleic acid</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>RNA</subject><subject>Serology</subject><subject>Severity of Illness Index</subject><subject>Substance abuse treatment</subject><subject>Surveys and Questionnaires</subject><subject>Tropical diseases</subject><subject>Vietnam - epidemiology</subject><subject>Virology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk99q2zAUxs3YWLtubzA2wWC0sGT6Z0u6GYSwzoHQlrbLrZBlOVZxrFSys-1F9ryTl7Q0pRfFFzbHv-876Ds6SfIewTEiDH29cb1vVTNeu9aMIUoJo_RFcogEwaMMQ_LywfdB8iaEGwhTwrPsdXKAGaJcZPQw-ZvbZQ0uvFs731nXAleBfLYY5dMFmDrbVkZ3pgQXqrOm7QL4ZbsaTMqNanUsz-3GeHBqC--CDeDS3PbW23YJcrOOii7WpuDaG9WtohrYFuTKrmvXLr-As9iwNr4FC2u6Vq3A8eTs8gogjDN88jZ5VakmmHe791Hy8_T79TQfzc9_zKaT-UizVHSjinEBickUVoIpprGAGc6MyginjJVFmpEMCW54pQWENGVUI1GwAhNkRIYxOUo-bn3XjQtyF2mQiHEGeeRFJGZbonTqRq69XSn_Rzpl5f-C80upYnK6MbJkFBFYUUM1pVAXvFC6iIPhSmhcMBK9vu269cXKlDpm4lWzZ7r_p7W1XLqNpDzlGMFocLI1qB_J8slcDjWICGKUZBsU2eNdM-9uexM6ubJBm6ZRrXH9cEZBqYjxsWegnFHGMUkj-ukR-nRoO2qpYi7xFrl4HD2YyglNCUU8RUMc4yeo-JRmZXW81pWN9T3ByZ4gMp353S1VH4KcXV0-nz1f7LOfH7C1UU1XB9f0w0KEfZBuQR0vfPCmuh8CgnLYyrs05LCVcreVUfbh4dzvRXdrSP4B7YkuDw</recordid><startdate>20160505</startdate><enddate>20160505</enddate><creator>Nguyen Truong, Tam</creator><creator>Laureillard, Didier</creator><creator>Lacombe, Karine</creator><creator>Duong Thi, Huong</creator><creator>Pham Thi Hanh, Phuc</creator><creator>Truong Thi Xuan, Lien</creator><creator>Chu Thi, Nga</creator><creator>Luong Que, Anh</creator><creator>Vu Hai, Vinh</creator><creator>Nagot, Nicolas</creator><creator>Tuaillon, Edouard</creator><creator>Dominguez, Stéphanie</creator><creator>Lemoine, Maud</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0104-9047</orcidid><orcidid>https://orcid.org/0000-0001-8772-9029</orcidid><orcidid>https://orcid.org/0000-0002-3493-2821</orcidid></search><sort><creationdate>20160505</creationdate><title>High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)</title><author>Nguyen Truong, Tam ; Laureillard, Didier ; Lacombe, Karine ; Duong Thi, Huong ; Pham Thi Hanh, Phuc ; Truong Thi Xuan, Lien ; Chu Thi, Nga ; Luong Que, Anh ; Vu Hai, Vinh ; Nagot, Nicolas ; Tuaillon, Edouard ; Dominguez, Stéphanie ; Lemoine, Maud</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abuse</topic><topic>Acquired immune deficiency syndrome</topic><topic>Adult</topic><topic>Adults</topic><topic>AIDS</topic><topic>Alcohol</topic><topic>Alcohol abuse</topic><topic>Alcohol use</topic><topic>Alcoholic beverages</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral therapy</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biology and life sciences</topic><topic>Care and treatment</topic><topic>CD4 antigen</topic><topic>Cirrhosis</topic><topic>Coinfection - drug therapy</topic><topic>Coinfection - epidemiology</topic><topic>Coinfection - virology</topic><topic>Complications and side effects</topic><topic>Cross-Sectional Studies</topic><topic>Disease control</topic><topic>Drug abuse</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Genotypes</topic><topic>Health aspects</topic><topic>Health care access</topic><topic>Health risks</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - epidemiology</topic><topic>Hepatitis C - virology</topic><topic>Hepatitis C virus</topic><topic>Hepatology</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - virology</topic><topic>Hospitals</topic><topic>Human health and pathology</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - virology</topic><topic>Liver diseases</topic><topic>Liver failure</topic><topic>Lopinavir</topic><topic>Male</topic><topic>Males</topic><topic>Medicine and health sciences</topic><topic>Multivariate analysis</topic><topic>Narcotics</topic><topic>Nevirapine</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>People and Places</topic><topic>Population</topic><topic>Public health</topic><topic>Ribonucleic acid</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>RNA</topic><topic>Serology</topic><topic>Severity of Illness Index</topic><topic>Substance abuse treatment</topic><topic>Surveys and Questionnaires</topic><topic>Tropical diseases</topic><topic>Vietnam - epidemiology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen Truong, Tam</creatorcontrib><creatorcontrib>Laureillard, Didier</creatorcontrib><creatorcontrib>Lacombe, Karine</creatorcontrib><creatorcontrib>Duong Thi, Huong</creatorcontrib><creatorcontrib>Pham Thi Hanh, Phuc</creatorcontrib><creatorcontrib>Truong Thi Xuan, Lien</creatorcontrib><creatorcontrib>Chu Thi, Nga</creatorcontrib><creatorcontrib>Luong Que, Anh</creatorcontrib><creatorcontrib>Vu Hai, Vinh</creatorcontrib><creatorcontrib>Nagot, Nicolas</creatorcontrib><creatorcontrib>Tuaillon, Edouard</creatorcontrib><creatorcontrib>Dominguez, Stéphanie</creatorcontrib><creatorcontrib>Lemoine, Maud</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale in Context : Opposing Viewpoints</collection><collection>Gale in Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen Truong, Tam</au><au>Laureillard, Didier</au><au>Lacombe, Karine</au><au>Duong Thi, Huong</au><au>Pham Thi Hanh, Phuc</au><au>Truong Thi Xuan, Lien</au><au>Chu Thi, Nga</au><au>Luong Que, Anh</au><au>Vu Hai, Vinh</au><au>Nagot, Nicolas</au><au>Tuaillon, Edouard</au><au>Dominguez, Stéphanie</au><au>Lemoine, Maud</au><au>Chemin, Isabelle A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2016-05-05</date><risdate>2016</risdate><volume>11</volume><issue>5</issue><spage>e0153744</spage><epage>e0153744</epage><pages>e0153744-e0153744</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected patients in Haiphong, Northern Vietnam. A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated adults with positive HCV serology completed a standardised epidemiological questionnaire and had a comprehensive liver assessment including hepatic elastography (Fibroscan®, Echosens). From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7-39.6) years, median CD4 count: 504 (361-624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA (median 6.19 (4.95-6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b (69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosis ≥F2 including 24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis, excessive alcohol consumption, estimated time duration from HCV infection, nevirapine and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibrosis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multivariate analysis. Using Fibroscan® as a gold standard, the high thresholds of AST-to-platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs = 0.93, 95%CI: 0.86-0.99 and 0.96 (0.92-0.99), respectively). In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>27148964</pmid><doi>10.1371/journal.pone.0153744</doi><orcidid>https://orcid.org/0000-0002-0104-9047</orcidid><orcidid>https://orcid.org/0000-0001-8772-9029</orcidid><orcidid>https://orcid.org/0000-0002-3493-2821</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2016-05, Vol.11 (5), p.e0153744-e0153744
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_1787084579
source PubMed (Medline); Publicly Available Content Database
subjects Abuse
Acquired immune deficiency syndrome
Adult
Adults
AIDS
Alcohol
Alcohol abuse
Alcohol use
Alcoholic beverages
Anti-HIV Agents - therapeutic use
Antiretroviral agents
Antiretroviral therapy
Antiviral Agents - therapeutic use
Biology and life sciences
Care and treatment
CD4 antigen
Cirrhosis
Coinfection - drug therapy
Coinfection - epidemiology
Coinfection - virology
Complications and side effects
Cross-Sectional Studies
Disease control
Drug abuse
Drug therapy
Drugs
Epidemiology
Female
Fibrosis
Genotypes
Health aspects
Health care access
Health risks
Hepatitis
Hepatitis C
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Hepatitis C - virology
Hepatitis C virus
Hepatology
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV Infections - epidemiology
HIV Infections - virology
Hospitals
Human health and pathology
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Life Sciences
Liver
Liver cirrhosis
Liver Cirrhosis - epidemiology
Liver Cirrhosis - etiology
Liver Cirrhosis - virology
Liver diseases
Liver failure
Lopinavir
Male
Males
Medicine and health sciences
Multivariate analysis
Narcotics
Nevirapine
Pathogenesis
Patients
People and Places
Population
Public health
Ribonucleic acid
Risk analysis
Risk factors
RNA
Serology
Severity of Illness Index
Substance abuse treatment
Surveys and Questionnaires
Tropical diseases
Vietnam - epidemiology
Virology
title High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T12%3A29%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20Proportion%20of%20HIV-HCV%20Coinfected%20Patients%20with%20Advanced%20Liver%20Fibrosis%20Requiring%20Hepatitis%20C%20Treatment%20in%20Haiphong,%20Northern%20Vietnam%20(ANRS%2012262)&rft.jtitle=PloS%20one&rft.au=Nguyen%20Truong,%20Tam&rft.date=2016-05-05&rft.volume=11&rft.issue=5&rft.spage=e0153744&rft.epage=e0153744&rft.pages=e0153744-e0153744&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0153744&rft_dat=%3Cgale_plos_%3EA453418513%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c759t-f78903e6a2a97a7c290626ea638477db5636198e8fc9004574c19b7b231e96223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1787084579&rft_id=info:pmid/27148964&rft_galeid=A453418513&rfr_iscdi=true